Kraig Labs Produces First Portion of Spider Silk to Fulfill First Commercial Order from Elite European Fashion Brand

July 17, 2025

Pioneering milestone brings first commercial spider silk sale within reach, as company scales infrastructure and advances hybrid silkworm systems

DENVER, Colo., Jul 17, 2025 (247marketnews.com)- Kraig Biocraft Laboratories (OTCQB:KBLB), the global leader in spider silk-based super fiber technology, recently announced that it completed another production batch of its proprietary BAM-1 spider silk, reaching approximately one-third of the total volume required to fulfill its first commercial order from a globally renowned European luxury fashion house.

This achievement underscores Kraig Labs’ position as a pioneer in bioengineered spider silk, a material highly prized for its exceptional properties. Spider silk has long been one of the most sought-after natural fibers due to its unmatched combination of strength, elasticity, and lightness. Five times stronger than steel by weight and more flexible than Kevlar, spider silk’s biocompatibility, biodegradability, and performance characteristics have applications across a wide range of industries and high-performance applications.

Its potential uses span multiple industries: in athletic apparel for durable, flexible, and sustainable performance wear; luxury textiles, fashion, couture, high-end apparel; in aerospace for lightweight composites that improve fuel efficiency; in defense for ballistic vests and parachute cords; in medical textiles for sutures, tissue scaffolds, and drug delivery systems; in construction for strong, lightweight structural reinforcements; in wearables for breathable, smart textiles that integrate electronics; and sustainability-focused materials.

The completion of this batch marks a pivotal moment in Kraig Labs’ transition from R&D to revenue-generating commercialization, bringing the Company one step closer to executing what would be the world’s first sale of bioengineered spider silk at scale.

Kraig Labs is on watch for the imminent completion of its first commercial spider silk sale, a pivotal milestone that positions the Company as the first to deliver bioengineered spider silk at scale.

In addition to the European based Global Luxury Brand, Kraig Labs stated that they “are in regular communication with…major Global brands that are standing by to receive their first shipments of materials.” Including “a world leader in high-end performance sportswear with an approved budget to buy silk from us” and “one of the world’s top 5 performance athletic equipment producers, looking for spider silk to integrate into their top-performing products. Supplying products to these three entities is the focus of our current production.”

Until now, spider silk’s commercial potential has remained largely untapped due to spiders’ territorial nature, which prevents traditional farming. Kraig Labs solved this with genetically engineered silkworms that can produce spider silk protein using existing commercial sericulture infrastructure, unlocking scalable production at significantly reduced cost compared to synthetic fermentation methods.

“Deploying two separate rearing centers for our parent lines is a key part of our strategy to build a reliable and scalable supply chain that can address the demand for spider silk and support year-round production,” said Kim Thompson, Founder and CEO of Kraig Labs. “This plan, which is the brainchild of our chief sericulture expert, Dr. Kumar, will provide the throughput necessary to support large-scale commercial production and a buffer against potential disruption.”

Building the World’s First Commercial Spider Silk Supply Chain

To meet the rising interest from global luxury brands and technical textile buyers, Kraig Labs is now executing a dual-pronged production expansion strategy. This includes:

  • A dual-facility rearing model to mitigate risks and boost capacity
  • A cold-storage diapausing system that allows near-continuous silk output and better control of hybrid silkworm cycles
  • Integration of new hybrid silkworm strains engineered for both high-quality fiber and increased survivability

“This latest batch brings us another step closer to delivering premium spider silk materials to one of the most recognized names in fashion,” said Jon Rice, Chief Operating Officer. “The shift to a diapausing hybrid system reflects our long-term vision to deliver the highest quality spider silk at commercial scale. By making this investment in time, infrastructure, and production strategy, we are positioning ourselves to meet the demand we see forming.”

A Turning Point for Kraig Labs

This milestone validates Kraig Labs’ unique vertical integration model, enabling it to maintain full control over R&D, strain development, and commercial-scale production. The Company’s BAM-1 and BAM-2 platforms are part of its broader spider silk pipeline, designed to meet both luxury aesthetic and performance durability specifications.

Kraig’s recent successes in optimizing silkworm survivability, yield, and fiber strength have laid the groundwork for 2025 and beyond. With growing demand from high-fashion, defense, and technical apparel sectors, Kraig Labs is emerging as the only company positioned to deliver spider silk at meaningful volumes and profitably.

Please click here for recent CEO letter to shareholders, please click here to read the full Kraig Labs analyst report on 247marketnews.com, or please visit www.kraiglabs.com for more information.

Coincidentally, Bolt Projects (NASDAQ:BSLK), which previously attempted to develop low performance spider silk fibers, is one of today’s top performing stocks.

Other listings of note are Top Wealth Group (NASDAQ:TWG), which entered into a legally-binding memorandum of understanding with Jilin Xiuzheng Agriculture and Animal Husbandry Technology, a member of Chinese Pharmaceutical Group Xiuzheng Group, for a proposed injection of animal-related (including pets and livestock) pharmaceutical products, foods and supplements business, and Windtree (NASDAQ:WINT), which entered into a $60 million securities purchase agreement led by Build and Build, with the potential for up to an additional $140 million in gross proceeds in future subscriptions, for total subscriptions of up to $200 million, to be primarily used to launch a BNB crypto treasury strategy and purchase BNB, positioning Windtree as a leader in the BNB digital asset.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

24/7 MARKET NEWS, INC Disclaimer

Please go to https://247marketnews.com/kblb-disclosure/ for disclaimer information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (KBLB, BSLK, TWG, WINT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.